185 related articles for article (PubMed ID: 24737166)
1. Prognostic relevance of glycosylation-associated genes in breast cancer.
Milde-Langosch K; Karn T; Schmidt M; zu Eulenburg C; Oliveira-Ferrer L; Wirtz RM; Schumacher U; Witzel I; Schütze D; Müller V
Breast Cancer Res Treat; 2014 Jun; 145(2):295-305. PubMed ID: 24737166
[TBL] [Abstract][Full Text] [Related]
2. Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
Legler K; Rosprim R; Karius T; Eylmann K; Rossberg M; Wirtz RM; Müller V; Witzel I; Schmalfeldt B; Milde-Langosch K; Oliveira-Ferrer L
Br J Cancer; 2018 Mar; 118(6):847-856. PubMed ID: 29381688
[TBL] [Abstract][Full Text] [Related]
3. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers.
Julien S; Ivetic A; Grigoriadis A; QiZe D; Burford B; Sproviero D; Picco G; Gillett C; Papp SL; Schaffer L; Tutt A; Taylor-Papadimitriou J; Pinder SE; Burchell JM
Cancer Res; 2011 Dec; 71(24):7683-93. PubMed ID: 22025563
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer.
Gretschel S; Haensch W; Schlag PM; Kemmner W
Oncology; 2003; 65(2):139-45. PubMed ID: 12931020
[TBL] [Abstract][Full Text] [Related]
5. Relevance of βGal-βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients.
Milde-Langosch K; Schütze D; Oliveira-Ferrer L; Wikman H; Müller V; Lebok P; Pantel K; Schröder C; Witzel I; Schumacher U
Breast Cancer Res Treat; 2015 Jun; 151(3):515-28. PubMed ID: 25975956
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of α-L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface.
Cheng TC; Tu SH; Chen LC; Chen MY; Chen WY; Lin YK; Ho CT; Lin SY; Wu CH; Ho YS
Oncotarget; 2015 Aug; 6(25):21283-300. PubMed ID: 26204487
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
9. Glycosyltransferases as marker genes for the quantitative polymerase chain reaction-based detection of circulating tumour cells from blood samples of patients with breast cancer undergoing adjuvant therapy.
Kölbl AC; Hiller RA; Ilmer M; Liesche F; Heublein S; Schröder L; Hutter S; Friese K; Jeschke U; Andergassen U
Mol Med Rep; 2015 Aug; 12(2):2933-8. PubMed ID: 25955084
[TBL] [Abstract][Full Text] [Related]
10. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T;
Clin Cancer Res; 2017 Dec; 23(23):7225-7231. PubMed ID: 28972041
[No Abstract] [Full Text] [Related]
11. Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.
Potapenko IO; Lüders T; Russnes HG; Helland Å; Sørlie T; Kristensen VN; Nord S; Lingjærde OC; Børresen-Dale AL; Haakensen VD
Mol Oncol; 2015 Apr; 9(4):861-76. PubMed ID: 25655580
[TBL] [Abstract][Full Text] [Related]
12. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
13. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin expression is associated with poor outcomes in breast cancer.
Li YR; Xian RR; Ziober A; Conejo-Garcia J; Perales-Puchalt A; June CH; Zhang PJ; Tchou J
Breast Cancer Res Treat; 2014 Oct; 147(3):675-84. PubMed ID: 25193277
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of ion channel genes predicts clinical outcome in breast cancer.
Ko JH; Ko EA; Gu W; Lim I; Bang H; Zhou T
Mol Cancer; 2013 Sep; 12(1):106. PubMed ID: 24053408
[TBL] [Abstract][Full Text] [Related]
16. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
[TBL] [Abstract][Full Text] [Related]
17. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.
Sicking I; Edlund K; Wesbuer E; Weyer V; Battista MJ; Lebrecht A; Solbach C; Grinberg M; Lotz J; Hoffmann G; Rahnenführer J; Hengstler JG; Schmidt M
PLoS One; 2014; 9(10):e111306. PubMed ID: 25340395
[TBL] [Abstract][Full Text] [Related]
18. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer.
Yang Y; Qian J; Xiang Y; Chen Y; Qu J
Oncotarget; 2017 Jan; 8(4):6833-6844. PubMed ID: 28036281
[TBL] [Abstract][Full Text] [Related]
20. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
